IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
Visa to Move European Headquarters to London’s Canary Wharf 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Asian Markets Mixed as RBI Cuts Rates and BOJ Signals Possible Hike 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Moderna is said to be mulling over creating its manufacturing partner in South Korea. This affiliate will be given the power to handle the production of its COVID-19 vaccines in the country, so there will be a local source.
Moderna’s plan for a Korean branch
Moderna’s plan to establish its Korean affiliate was revealed on Tuesday, April 20. The US-based biotech company also thinks that setting up a local branch in S. Korea is a first step to boost its production capacity in Asia.
"As far as our understanding goes, Moderna plans to strengthen its vaccine production capabilities by establishing affiliates in Korea, Japan and Australia this year,” The Korea Times quoted Park Byung Kuk, an analyst at NH Investment, as saying. “Once the establishment process is done, Moderna could use a Korean company as its contract manufacturing organization (CMO) partner to manufacture its COVID-19 vaccines."
It was said that this information about the possibility of Moderna creating a branch in S. Korea was based on Park’s observation and understanding during Moderna’s in-house event that was held last April 15. The analyst said that at that time, the biotech firm repeatedly mentioned that it might establish an affiliate in S. Korea.
Explaining the CMO business set up
It was noted that the CMO business setup had become a favorite strategy among the country’s pharmaceutical and biotech firms as the spread of coronavirus continues. In this business arrangement, the CMOs take orders from clients and then produce the medicines on a consignment basis.
Now, it was suggested that if Moderna enters S. Korea, this will be the same setup once it starts the business. It was added that if the plan pushes through, it is likely that GC Pharma and Hanmi Pharm would be considered as Moderna’s CMO partners due to their manufacturing capabilities.
Finally, Moderna’s plan to do business in S. Korea is actually not something new. In fact, in February, Fierce Pharma reported that Moderna is considering the construction of a $200 million vaccine factory in Seoul. This will mainly produce vaccines to be supplied in the Asian market, but there was no confirmation for this project yet.
